Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft‐tissue sarcoma

Olaratumab, a monoclonal antibody targeting human platelet‐derived growth factor receptor α, plus doxorubicin significantly improved overall survival in patients with advanced soft‐tissue sarcoma (STS) in a prior phase 1b/2 randomized trial. Subsequent exposure‐response analysis suggested that highe...

Descripción completa

Detalles Bibliográficos
Autores principales: Yonemori, Kan, Kodaira, Makoto, Satoh, Taroh, Kudo, Toshihiro, Takahashi, Shunji, Nakano, Kenji, Ando, Yuichi, Shimokata, Tomoya, Mori, Joji, Inoue, Koichi, Oakley, Gerard J., Sakaguchi, Sachi, Tamura, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6272083/
https://www.ncbi.nlm.nih.gov/pubmed/30353601
http://dx.doi.org/10.1111/cas.13846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6272083/
https://www.ncbi.nlm.nih.gov/pubmed/30353601
http://dx.doi.org/10.1111/cas.13846

Ejemplares similares